论文部分内容阅读
目的 观察胃泌素拮抗剂对大肠癌肝转移患者的治疗效果。方法 对照组 3 8例常规化疗 ;治疗组 46例除常规化疗外同时服用胃泌素受体拮抗剂丙谷胺 12 0 0mg/d。两组患者每月定期随访 1次。 结果 对照组患者 1年内肝脏转移癌最大径增加 8.1± 2 .2cm ,死亡率为 5 5 .3 % ( 2 1/3 8) ;治疗组患者肝脏转移癌 1年内最大径增加 3 .5± 1.2cm ,死亡率为 2 1.7% ( 10 /46) ,均明显低于对照组 (P <0 .0 1)。结论 用胃泌素受体拮抗剂对大肠癌肝转移患者进行治疗 ,可以延缓肿瘤生长 ,延长患者生存时间 ,降低患者死亡率。
Objective To observe the therapeutic effect of gastrin antagonist on patients with liver metastasis from colorectal cancer. Methods Control group of 38 routine chemotherapy; 46 cases of treatment group in addition to conventional chemotherapy while taking gastrin receptor antagonist plasma valproate 120 mg / d. Two groups of patients were regularly followed up once a month. Results In the control group, the maximum diameter of metastatic liver cancer increased by 8.1 ± 2.2cm and the mortality rate was 55.3% (2 1/3 8) within 1 year. In the treatment group, the maximum diameter of metastatic liver cancer increased by 3.5 ± 1.2 cm, and the mortality rate was 2 1.7% (10/46), which were significantly lower than those in the control group (P <0.01). Conclusion Gastrin receptor antagonist for patients with liver metastasis of colorectal cancer treatment can delay tumor growth, prolong survival time and reduce patient mortality.